Insmed Incorporated — Form 10-Q Summary
Reporting period: Quarter ended September 30, 2023; comparisons are with the three and nine months ended September 30, 2022, unless otherwise noted. Amounts are in U.S. dollars. Insmed is a commercial-stage biopharmaceutical company whose sole marketed product is ARIKAYCE; its pipeline includes brensocatib, TPIP and early-stage programs.
Financial performance and liquidity
| Metric | Q3 2023 | Q3 2022 | Nine months 2023 | Nine months 2022 |
|---|---|---|---|---|
| Net product revenue | $79.1 million | $67.7 million | $221.5 million | $186.1 million |
| Operating loss | $147.7 million | $127.7 million | $531.4 million | $305.8 million |
| Net loss | $158.9 million | $131.1 million | $563.5 million | $321.4 million |
| Basic and diluted loss per share | $1.11 | $1.09 | $4.06 | $2.68 |
| Operating cash used | Not separately provided for quarter | Not separately provided for quarter | $405.4 million | $297.3 million |
- Q3 ARIKAYCE revenue grew 16.7% year over year: U.S. sales rose 19.5%, Japan 10.7%, and Europe/rest of world 3.5%. Nine-month revenue increased 19.1%, with growth across all reported geographies.
- Cost of product revenue, excluding intangible amortization, was 21.1% of revenue in Q3 versus 19.9% a year earlier; for nine months it was 21.3% versus 22.6%. Corresponding product gross margins before intangible amortization were approximately 78.9% and 80.1% for Q3, and 78.7% and 77.4% for the nine-month periods.
- At September 30, cash and cash equivalents were $487.1 million and marketable securities were $298.8 million, totaling $785.9 million. Working capital was $729.8 million. Cash and cash equivalents declined $586.9 million from year-end 2022, principally reflecting operating cash use and purchases of marketable securities.
- Long-term debt was $1.148 billion, including $800 million face value of convertible notes and a term loan with $359.4 million carrying value. The separate royalty financing liability was $153.4 million. The term loan bears SOFR, subject to a 2.5% floor, plus 7.75%; the company had capitalized $17.2 million of paid-in-kind interest in the first nine months.
- Total assets were $1.325 billion and total liabilities were $1.614 billion; shareholders’ equity was negative $289.4 million. Shares outstanding were 143.0 million at September 30, 2023.
Material changes and unusual items
- Research and development expense rose 59.1% for the first nine months to $434.0 million, including $86.7 million of non-cash acquired in-process R&D expense for the Adrestia and Vertuis asset acquisitions. Excluding this acquisition expense, R&D still increased, reflecting clinical development, staffing and other research costs.
- Selling, general and administrative expense increased 32.6% for nine months to $255.0 million, driven in part by brensocatib commercial-readiness spending and higher personnel costs.
- Nine-month interest expense rose to $60.9 million from $10.0 million, principally due to the term loan and OrbiMed royalty financing entered into in 2022. Investment income increased to $32.3 million from $2.8 million as cash investments and interest rates rose.
- The company recorded a $13.0 million nine-month expense from changes in fair value of deferred and contingent acquisition consideration, versus a $19.0 million gain in the prior-year period. It also recorded a $1.7 million loss from the interest-rate swap fair-value change.
- In June 2023, Insmed issued shares valued at $72.4 million to acquire Adrestia; potential additional cash milestones total up to $326.5 million, plus royalties. Vertuis was acquired in January. The company also raised $37.5 million net through its at-the-market share program in Q2.
Outlook, management commentary and risks
- Management expects continued operating losses and substantial cash requirements. It stated that available funds should cover financial needs for at least the next 12 months, while noting it may seek additional capital. No specific revenue, earnings or cash-burn guidance was provided.
- Management expected R&D and SG&A expense to continue increasing in 2023 versus 2022, reflecting clinical-trial activity and brensocatib launch-readiness work.
- Brensocatib’s Phase 3 ASPEN trial completed enrollment in Q1 2023; topline results were anticipated in Q2 2024. The Phase 2b BiRCh trial in chronic rhinosinusitis without nasal polyps was nearing first-patient randomization.
- ARIKAYCE’s ARISE study met its objective of validating the QOL-B respiratory domain as a patient-reported outcome tool. Insmed planned to propose it as ENCORE’s primary endpoint; ENCORE enrollment was expected to continue into 2024, subject to further FDA discussions, with topline results anticipated in 2025. ARIKAYCE retains U.S. accelerated approval and requires a confirmatory trial for full approval.
- For TPIP, the company reported interim, blended/blinded Phase 2 observations, including dose-titration and safety information, and planned to share PH-ILD topline results in the first half of 2024. Management emphasized that interim observations may not predict final results; it was exploring a higher maximum dose for certain PAH patients.
- Key risks include clinical-trial failure or delay, regulatory uncertainty, ARIKAYCE market acceptance and reimbursement, dependence on a limited number of manufacturers, competition, financing needs and debt/royalty obligations. Three customers represented 88% of gross product revenue for the first nine months of 2023. The company reported difficulty reaching nationally reimbursed pricing agreements in Germany and Italy. Management did not expect ordinary-course legal proceedings to have a material adverse effect.
Important facts for investors to verify
- Whether ARIKAYCE revenue growth and product margins continue, and how customer concentration and reimbursement access affect sales.
- ASPEN topline timing and results, FDA alignment on ENCORE’s endpoint and enrollment, and the path to full U.S. approval for ARIKAYCE.
- Final efficacy, safety and tolerability results for TPIP; interim data are blinded and may differ materially from completed-trial results.
- Cash runway against operating cash use, planned development and commercialization spending, and potential need for additional financing.
- Debt service and variable-rate exposure, the royalty financing’s sales-linked payments and minimum-payment provisions, and potential dilution from equity issuance and convertible notes.
- Potential acquisition milestone obligations and the assumptions underlying contingent consideration fair values.